Various recent developments are driving an evolution in the way PRO measures are developed. For example, drug regulatory agencies (e.g. the FDA) can now be more substantively involved or consulted on measure development work; the patients’ role is now seen as going beyond being a study subject to being involved as research partners. Use of modern test theory in development of scoring algorithms and overall measure development work is now the new ‘gold standard’.
|Title of host publication||Living with Chronic Disease: Measuring Important Patient-Reported Outcomes|
|Place of Publication||Singapore|
|Number of pages||34|
|Publication status||Published - 7 Sep 2018|